Aclaris TherapeuticsACRS +1.73%38 Days Payable is 711.65 as of Mar. 2026, which is 32% above its 10-year median of 539.39. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 706 Biotechnology companies, Aclaris Therapeutics ranks better than 79.04% on this metric.
The historical rank and industry rank for Aclaris Therapeutics's Days Payable or its related term are showing as below:
ACRS'
s Days Payable Range Over the Past 10 Years
Min: 160.19 Med: 539.39 Max: 1612.86
Current: 504.58
During the past 13 years, Aclaris Therapeutics's highest Days Payable was 1612.86. The lowest was 160.19. And the median was 539.39.
ACRS's Days Payable is ranked better than 79.04% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs ACRS: 504.58
Aclaris Therapeutics's Days Payable
increased
from Mar. 2025 (332.38) to Mar. 2026 (711.65).
It may suggest that Aclaris Therapeuticsdelayed paying its suppliers.
Aclaris Therapeutics Days Payable Related Terms
Aclaris Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Aclaris Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aclaris Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aclaris Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (ACRS) has a Days Payable of 711.65 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aclaris Therapeutics and its competitors. This is 32% above median its historical median of 539.39. Over the past decade, Aclaris Therapeutics' Days Payable has ranged from 160.19 to 1,612.86. According to the industry distribution chart, Aclaris Therapeutics ranks #148 out of 706 companies in the Biotechnology industry, placing it in the top 21%.
Is Aclaris Therapeutics' Days Payable too high?
Aclaris Therapeutics' current Days Payable of 711.65 is 32% above median its 10-year median of 539.39. Over the past 10 years, this metric has ranged from a low of 160.19 to a high of 1,612.86. The Biotechnology industry median Days Payable is 113.56. Aclaris Therapeutics' value of 711.65 is 526.7% above this industry median. Based on the distribution chart, Aclaris Therapeutics ranks #148 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Days Payable compare to RLMD and GYRE?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #148 out of 706 companies for Days Payable. This places Aclaris Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Aclaris Therapeutics' value of 711.65 is 526.7% above this benchmark. Historically, Aclaris Therapeutics' own Days Payable has ranged from 160.19 to 1,612.86 over the past decade. While the company's 10-year median is 539.39 vs. the industry median of 113.56, Aclaris Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aclaris Therapeutics's current Days Payable of 711.65 is 526.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aclaris Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclaris Therapeutics's current Days Payable is 711.65, which is 32% above median its own 10-year median of 539.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.00 — trading 1011.1% above its estimated fair value. The current Days Payable is 711.65, which is 32% above median its 10-year median of 539.39 and 526.7% above the Biotechnology industry median of 113.56. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Days Payable is 711.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aclaris Therapeutics (ACRS) Overvalued in 2026?
Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued.
The current stock price of $5.00 is trading 1011.1% above its estimated GF Value™ of $0.45.
GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.
Key valuation signals for ACRS:
Days Payable: 711.65 (32% above median its 10-year median of 539.39)
GF Value™: $0.45 vs. price of $5.00 (1011.1% above fair value)
Industry Position: 526.7% above the Biotechnology median (#148 of 706)
No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score
Get the complete analysis for ACRS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRS has been successfully added to your 
